NYU Langone is among the first U.S. centers using magnetic compression anastomosis, a novel technology that replaces staples with self-forming magnets to reconnect sections of the digestive tract during GI surgery. Surgeons believe it could represent the first major advance in bowel connection techniques in decades, with the potential to reduce complications such as bleeding, leaks, and strictures while shortening procedure times. Although currently being used in bariatric surgery, researchers see broader applications across GI surgery and even future endoscopic procedures if clinical outcomes continue to prove favorable.
Author: Abhay Panchal
A large study of more than 11,000 patients found that virtual multidisciplinary GI care—combining gastroenterology, nutrition, behavioral health, and care coordination—was associated with high levels of symptom improvement and control. Patients had a median wait time of just 6 days for their initial appointment, and outcomes improved with greater engagement. Among those completing four or more visits, 92.4% reported symptom improvement, 94.7% achieved symptom control, and 98.1% reported only mild or no symptoms. The study also found that involvement from dietitians and behavioral health specialists contributed significantly to symptom improvement, supporting the value of integrated, team-based GI care delivered virtually.
This is one of those articles that stays with you—not because of a shocking statistic, but because of the deeply human stories behind it. Three physicians who once viewed medicine as their calling share why they ultimately walked away. Their reasons differ—bullying during surgical training, loss of identity, moral injury from healthcare economics, and relentless administrative burdens—but a common theme emerges: many doctors aren’t leaving because they stopped caring; they’re leaving because the system made it increasingly difficult to care the way they wanted to. What makes the article compelling is that it goes beyond burnout headlines and explores a…
Overlap of symptoms in eosinophilic esophagitis and other conditions such as gastroesophageal reflux disease can make careful and accurate diagnosis of EoE challenging for clinicians. But timely, accurate diagnosis of EoE is crucial so that patients can benefit from available therapeutic options. When managing patients who present with esophageal eosinophilia, “we need to make sure it is eosinophilic esophagitis and not another cause,” such as GERD, stressed Bryan Sauer, MD, MSc, the founder and co-director of the University of Virginia’s Adult Multidisciplinary EoE Program, in Charlottesville. Compared with people who have GERD, those with EoE are younger, are more likely…
Edulis Therapeutics is developing a bioresorbable, endoscopically delivered drug depot designed to provide sustained, localized therapy for chronic GI conditions such as stricturing Crohn’s disease. The platform functions like a “drug-eluting stent for the GI tract,” allowing gastroenterologists to place a biodegradable implant during routine endoscopy that releases medication directly at the disease site over time. By targeting therapy locally, the company aims to reduce systemic drug exposure while potentially delaying or preventing interventions such as balloon dilation, stricturoplasty, or surgery. Fresh off winning both the AGA and DDW Shark Tank competitions, Edulis is advancing through preclinical studies and exploring…
A large real-world study from China found that AI-assisted upper endoscopy nearly doubled the detection of high-risk gastric lesions (HrGLs), including early gastric cancer and gastric dysplasia. After matching more than 15,500 patients, researchers reported a HrGL detection rate of 0.94% with AI assistance versus 0.48% without AI, representing a nearly 2-fold improvement. The benefit was observed across multiple lesion types, including early gastric cancer, and was particularly pronounced when AI was used by experienced endoscopists and during sedated procedures. The findings add to growing evidence that AI can enhance lesion detection beyond colonoscopy, suggesting a potential role in improving…
Gastroenterology continues to evolve rapidly as advances in colorectal cancer prevention, inflammatory bowel disease research, microbiome science and outpatient digestive care reshape the specialty. Across the U.S., gastroenterologists are leading breakthroughs in clinical research, patient education, quality improvement and healthcare policy while helping improve outcomes for millions of patients with digestive diseases. The following physicians stand out for their clinical expertise, scientific contributions and leadership in gastroenterology.
Unio Health Partners has partnered with Thesis Care to deploy AI-powered care team agents across its urology, gastroenterology, and radiation oncology practices, which collectively serve more than 500,000 patients annually. The AI agents will support workflows such as care gap closure, patient engagement, and prior authorizations, aiming to expand clinical capacity without increasing administrative burden on physicians and staff. Unlike standalone AI tools, the Thesis model combines AI agents with human clinical teams to complete operational tasks within existing healthcare workflows. The partnership highlights a growing trend in specialty care: using AI not for diagnosis or procedures, but to automate…
Amplified Sciences is developing an ultra-sensitive diagnostic platform aimed at improving the early detection and risk stratification of pancreatic cysts, a key challenge in preventing pancreatic cancer. The company’s lead product, PanCystPro™, uses a combination of three biomarkers—including the protease gastricsin, glucose, and CEA—along with machine learning algorithms to help distinguish potentially precancerous pancreatic cysts from benign lesions. The goal is to reduce both unnecessary surgeries and missed opportunities for early cancer intervention. A graduate of the inaugural AGA Incubator cohort, Amplified Sciences has already launched early-access clinical sites and is collaborating with institutions including UCSF, Stanford, Indiana University, and…
Jona has expanded its Clinical Gut Microbiome Analysis platform by adding stool biomarkers such as calprotectin, secretory IgA, and short-chain fatty acids alongside deep shotgun metagenomic sequencing and its AI-powered interpretation engine. The company says the enhanced test combines microbiome sequencing, stool chemistry, and an AI model trained on more than 220,000 scientific studies to provide clinicians with more actionable insights into gut health. Jona also uses a “Digital Twin” technology designed to simulate how diet, supplements, and lifestyle changes may influence an individual’s microbiome before interventions are implemented. The launch reflects a broader trend in microbiome diagnostics: moving beyond…